Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Simcere Steps Up Efforts In Antitumor Sector

This article was originally published in PharmAsia News

Executive Summary

Simcere Pharmaceutical Group has launched its antitumor drug Jiebaishu (Nedaplatin for injection) on a high note in Beijing, Shanghai and Guangzhou. The drug became a brand under the company since it acquired 85.7 percent stake in Nanjing Dongjie Pharmaceutical late last year. Added to its Endostar purchase in 2006, the company has developed into a sizable force in the antitumor sector. According to Simcere, Jiebaishu currently accounts for over 80 percent of Nedaplatin's domestic market share. Simcere's strategy focuses on the business of innovative drugs or branded but off-patent drugs by first launching in China. Antitumor drugs are ideal for such a model and the company believes product-oriented acquisition is key to reaching its target market. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts